Jakarta. Pharmaceutical company Phapros (PEHA) posted consolidated sales of Rp 940.88 billion ($52.2 million) in 2025, up 26.34% from Rp 744.7 billion ($41.3 million) a year earlier, as growth across its product portfolio helped the company return to profitability.

“This achievement reflects the success of the company's business fundamentals strategy implemented throughout 2024-2025, including supply-chain improvements, strengthened commercialization efforts, and diversification of customer segments,” Finance, Risk Management, and Human Capital Director Ferdinand Troedum said on Thursday.

Phapros, a subsidiary of state-owned pharmaceutical holding company Bio Farma, recorded a net profit of Rp 27.4 billion ($1.5 million) in 2025, compared with a net loss of Rp 290.6 billion in the previous year. The turnaround was driven by double-digit sales growth and efficiency measures that reduced production and operating costs.

Sales increased across all major product categories. Over-the-counter medicine sales rose 43.2% year-on-year, while generic drug sales grew 13.95% and ethical products recorded a 55% increase.

President Director Intan Abdams Katoppo said the company would focus on strengthening financial sustainability, improving working-capital management, and expanding higher-margin products in 2026.

Phapros is also targeting export growth in Timor-Leste, Cambodia, the Philippines, Myanmar, Papua New Guinea, and Peru.

The company further improved its balance sheet by reducing liabilities by 7.45% to Rp 959.7 billion in 2025.

The positive momentum continued into 2026. Ferdinand said first-quarter sales rose 10.17% year-on-year to Rp 221 billion, while operating cash flow reached Rp 37.2 billion, compared with a negative cash-flow position in the same period last year.

Phapros has also prepared a series of mitigation measures to cushion the impact of the rupiah's depreciation, particularly on imported raw materials and shipping costs.

Production Director Ida Rahmi Kurniati said the company is focusing on internal initiatives to minimize the effects of exchange-rate volatility.

“As exchange-rate fluctuations are external factors beyond our control, Phapros is focusing on measures within our control to mitigate their impact,” Ida said.

The company is pursuing hedging strategies, diversifying raw-material suppliers, and seeking procurement efficiencies to manage rising costs.

Phapros has also secured part of its raw-material requirements through procurement contracts negotiated at the beginning of the year, helping shield the company from short-term price volatility.

In addition, the company is renegotiating with overseas suppliers and considering longer-term contracts to maintain pricing stability while ensuring supply continuity, Ida said.